scholarly article | Q13442814 |
P356 | DOI | 10.1038/SREP09694 |
P8608 | Fatcat ID | release_coztulbbnff7fefpbvm5cyi6l4 |
P932 | PMC publication ID | 4894437 |
P698 | PubMed publication ID | 25853502 |
P50 | author | Xuejun Wang | Q38361109 |
P2093 | author name string | Xin Chen | |
Chong Zhao | |||
Jinbao Liu | |||
Xiaofen Li | |||
Hongbiao Huang | |||
Ningning Liu | |||
Shouting Liu | |||
Dan Zang | |||
Yuning Liao | |||
Xianping Shi | |||
Peiquan Zhang | |||
Xiaoying Lan | |||
P2860 | cites work | Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis | Q24306444 |
AKT/PKB signaling: navigating downstream | Q24657857 | ||
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma | Q24672476 | ||
Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway | Q24678660 | ||
X-ray crystal structure of an IkappaBbeta x NF-kappaB p65 homodimer complex | Q27640955 | ||
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma | Q27824784 | ||
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 | ||
Stromal gene signatures in large-B-cell lymphomas | Q28302107 | ||
In vitro and in vivo toxicity of garcinia or hydroxycitric Acid: a review. | Q30420693 | ||
Organization and regulation of mitogen-activated protein kinase signaling pathways | Q33333640 | ||
Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins | Q33345150 | ||
A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 | ||
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo | Q33896749 | ||
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. | Q54621049 | ||
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia | Q83362579 | ||
The regulatory roles of apoptosis-inducing factor in the formation and regression processes of ocular neovascularization. | Q34276196 | ||
Physiological levels of ATP negatively regulate proteasome function. | Q34376187 | ||
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors | Q34754412 | ||
Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823 | Q35045429 | ||
Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly | Q35090607 | ||
Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression | Q35663874 | ||
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study | Q35849663 | ||
NF-kB in development and progression of human cancer | Q36108761 | ||
Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells | Q36369816 | ||
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. | Q37109227 | ||
Engaging the lysosomal compartment to combat B cell malignancies | Q37286690 | ||
PI3K/Akt: getting it right matters | Q37310202 | ||
Old target new approach: an alternate NF-kappaB activation pathway via translation inhibition | Q37338854 | ||
Gambogic acid covalently modifies IkappaB kinase-beta subunit to mediate suppression of lipopolysaccharide-induced activation of NF-kappaB in macrophages | Q37341200 | ||
Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation | Q37610733 | ||
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 | ||
Evaluation of the safety and efficacy of hydroxycitric acid or Garcinia cambogia extracts in humans | Q38005203 | ||
Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition | Q39435523 | ||
A novel inhibitor of focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma. | Q39484336 | ||
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis | Q40102590 | ||
Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells | Q40356831 | ||
Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells | Q40534739 | ||
Discovery and SAR of indole-2-carboxylic acid benzylidene-hydrazides as a new series of potent apoptosis inducers using a cell-based HTS assay | Q40547658 | ||
Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. | Q40560316 | ||
IkappaBbeta, but not IkappaBalpha, functions as a classical cytoplasmic inhibitor of NF-kappaB dimers by masking both NF-kappaB nuclear localization sequences in resting cells | Q40778669 | ||
Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo | Q43675946 | ||
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | Q43864036 | ||
Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1. | Q44623095 | ||
Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. | Q45197519 | ||
Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation | Q46110608 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | diffuse large B-cell lymphoma | Q2626074 |
B-cell lymphoma | Q4833719 | ||
gambogic acid | Q105007431 | ||
P304 | page(s) | 9694 | |
P577 | publication date | 2015-04-08 | |
P1433 | published in | Scientific Reports | Q2261792 |
P1476 | title | Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition | |
P478 | volume | 5 |
Q43226621 | A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy |
Q38965229 | Gambogic Acid and Its Role in Chronic Diseases. |
Q64109949 | Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis |
Q47826416 | Gambogic acid-loaded PEG-PCL nanoparticles act as an effective antitumor agent against gastric cancer. |
Q38632963 | Natural products against hematological malignancies and identification of their targets |
Q37355552 | Novel Natural Product-like Caged Xanthones Bearing a Carbamate Moiety Exhibit Antitumor Potency and Anti-Angiogenesis Activity In vivo |
Q33801982 | Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition |
Q92108627 | Potential Anticancer Agents Characterized from Selected Tropical Plants |
Q47631097 | Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing |